Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael James McClellan. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael James McClellan has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) EVP, Chief Financial Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael James McClellan. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Michael James McClellan as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2019-11-06 2019-11-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -695 0 -100.00
2019-11-06 2019-11-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
S - Sale X -242 15,898 -1.50 8.83 -2,138 140,447
2019-11-06 2019-11-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 695 16,140 4.50
2019-09-20 2019-09-18 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -4,091 0 -100.00
2019-09-20 2019-09-18 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
S - Sale X -1,406 15,445 -8.34 7.83 -11,011 120,957
2019-09-20 2019-09-18 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 4,091 16,851 32.06
2019-03-19 2019-03-18 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
S - Sale X -230 12,760 -1.77 16.63 -3,824 212,141
2019-03-19 2019-03-17 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -660 661 -49.96
2019-03-19 2019-03-17 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 660 12,990 5.35
2019-03-06 2019-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 50,746 50,746
2019-03-05 2019-03-04 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
S - Sale X -363 12,330 -2.86 16.88 -6,129 208,176
2019-03-05 2019-03-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -1,049 2,099 -33.32
2019-03-05 2019-03-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 1,049 12,693 9.01
2018-11-07 2018-11-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -695 695 -50.00
2018-11-07 2018-11-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
S - Sale -346 11,644 -2.89 22.73 -7,865 264,693
2018-11-07 2018-11-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 695 11,990 6.15
2018-03-20 2018-03-19 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
S - Sale -287 11,295 -2.48 17.88 -5,131 201,937
2018-03-20 2018-03-17 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -660 1,321 -33.32
2018-03-20 2018-03-17 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 660 11,582 6.04
2018-03-06 2018-03-05 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
F - Taxes -455 10,922 -4.00 19.38 -8,818 211,674
2018-03-06 2018-03-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
M - Exercise -1,049 3,148 -24.99
2018-03-06 2018-03-03 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
M - Exercise 1,049 11,377 10.16
2018-03-06 3/A TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
10,328
2018-02-12 2018-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Restricted Share Units
A - Award 48,361 48,361
2018-02-12 2018-02-09 4 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Stock Options (right to buy)
A - Award 123,288 123,288
2018-01-02 3 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
20,654
2018-01-02 3 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Ordinary Shares
20,654
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)